Loading...
Please wait, while we are loading the content...
Similar Documents
Chemotherapy with Irinotecan (CPT-11), a Topoisomerase-I Inhibitor, for Refractory and Relapsed Non-Hodgkin's Lymphoma
| Content Provider | Scilit |
|---|---|
| Author | Takag, Toshiyuki Saotome, Takashi |
| Copyright Year | 2001 |
| Description | Journal: Leukemia & Lymphoma Irinotecan hydrochloride (CPT-11), a DNA topoisomerase-I inhibitor, is now widely used in the treatment of various solid tumors, including colorectal, gastric, breast, lung, and ovarian cancer. Despite the good response shown in the late phase-II study, CPT-11 was not often employed in the treatment of malignant lymphoma, mainly because of severe leukopenia and diarrhea caused by the recommended schedule: 40 mg/m2 of CPT-11 on days 1 to 3, 8 to 10, 15 to 17, then discontinued for at least 2 weeks. In clinical use, administration of CPT-11 had to be ceased on days 15 to 17 in almost all cases, and on days 8 to 10 in a considerable number of patients. Subsequently, a lower dose schedule (less than 40 mg/m2) was developed. Our phase II trial employing a reduced dose of CPT-11 on days 1 and 2, plus ADM on day 3 with 3-week interval in patients with refractory and relapsed NHL showed a fairly good response of relapsed B-cell lymphoma and a substantial response of T-cell lymphoma with acceptable toxicity. The combination of a topoisomerase-I inhibitor (CPT-11) and a topoisomerase-II inhibitor is an interesting concept for the treatment of NHL. Another phase II trial in combination with CPT-11 and other anti-cancer drugs, particularly cisplatin or topoisomerase-II inhibitors, is warranted. A superior salvage chemotherapy regimen could be found in the future by investigating combinations of low-dose CPT-11 and cisplatin or topoisomerase-II inhibitors. |
| Related Links | http://www.tandfonline.com/doi/pdf/10.3109/10428190109099317 |
| Ending Page | 586 |
| Page Count | 10 |
| Starting Page | 577 |
| ISSN | 10428194 |
| e-ISSN | 10292403 |
| DOI | 10.3109/10428190109099317 |
| Journal | Leukemia & Lymphoma |
| Issue Number | 4 |
| Volume Number | 42 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2001-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Leukemia & Lymphoma Topoisomerase I Inhibitor Ovarian Cancer Chemotherapy Hodgkin's Lymphoma Topoisomerase Ii Inhibitors |
| Content Type | Text |
| Subject | Hematology Cancer Research Oncology |
